Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12142178 | 0.80 | DPP4 (0.40) | P2RX7DPP4KDM4ETSHRPOLB | |
| SCHEMBL12143432 | 0.75 | PER2 (0.43) | PER2CRY2 | |
| SCHEMBL12143430 | 0.73 | MAPT (0.55) | P2RX7KDM4ETSHRALDH1A1TDP1 | |
| SCHEMBL16423951 | 0.69 | GAA (0.51) | TSHRPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL758907 | 0.69 | ACE (0.42) | PER2CRY2L3MBTL1 | |
| SCHEMBL12143801 | 0.67 | KDM4E (0.48) | P2RX7KDM4EPOLBALDH1A1TDP1 | |
| SCHEMBL7442356 | 0.66 | L3MBTL1 (0.49) | PER2CRY2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL28677943 | 0.66 | PER2 (0.40) | PER2CRY2L3MBTL1 | |
| SCHEMBL15468337 | 0.65 | PER2 (0.40) | PER2CRY2DPP4 | |
| SCHEMBL4525501 | 0.64 | P2RX7 (0.45) | P2RX7KDM4ESMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | PER2 4034/4885CRY2 2092/4885P2RX7 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.